Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 5, 2010, Pages 931-938

  Zhai, Bing ^a   Zhou, Henry ^b   Yang, Liangpeng ^b   Zhang, Jun ^b   Jung, Kathy ^c   Giam, Chou Zen ^b   Xiang, Xin ^b   Lin, Xiaorong ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Antibiotic; Antifungal; Combination therapy; Fungal membrane

Indexed keywords

FLUCONAZOLE; POLYMYXIN B; PYRROLE; ANTIFUNGAL AGENT;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLUS; CANDIDA ALBICANS; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG POTENTIATION; DRUG SCREENING; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; HUMAN; HUMAN CELL; NONHUMAN; DRUG EFFECT; FUNGUS; MICROBIAL VIABILITY;

ANTIFUNGAL AGENTS; DRUG SYNERGISM; FLUCONAZOLE; FUNGI; MICROBIAL VIABILITY; POLYMYXIN B;

EID: 77953689696     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq046     Document Type: Article

References (79)

1. Anaissie EJ. Diagnosis and therapy of fungal infection in patients with leukemia-new drugs and immunotherapy. Best Pract Res Clin Haematol 2008; 21: 683-90.
2. Meunier F, Lukan C. The First European Conference on Infections in Leukaemia-ECIL1: a current perspective. Eur J Cancer 2008; 44: 2112-7.
3. Black KE, Baden LR. Fungal infections of the CNS: treatment strategies for the immunocompromised patient. CNS Drugs 2007; 21: 293-318.
4. Bohme A, Karthaus M. Systemic fungal infections in patients with hematologic malignancies: indications and limitations of the antifungal armamentarium. Chemotherapy 1999; 45: 315-24.
5. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995; 8: 515-48.
6. Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003; 37 Suppl 3: S157-87.
7. van der Horst CM, Saag MS, Cloud GA et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337: 15-21.
8. Pitisuttithum P, Tansuphasawadikul S, Simpson AJ et al. A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B. J Infect 2001; 43: 226-33.
9. Filioti J, Spiroglou K, Panteliadis CP et al. Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome. Intensive Care Med 2007; 33: 1272-83.
10. Powderly WG. Recent advances in the management of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22 Suppl 2: S119-23.
11. Latge J-P, Steinbach WJ. Aspergillus fumigatus and Aspergillosis. Washington, DC: ASM Press, 2009.
12. Longley N, Muzoora C, Taseera K et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 2008; 47: 1556-61.
13. Pukkila-Worley R, Mylonakis E. Epidemiology and management of cryptococcal meningitis: developments and challenges. Expert Opin Pharmacother 2008; 9: 1-10.
14. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol 2003; 11: 272-9.
15. Georgopapadakou NH. Antifungals: mechanism of action and resistance, established and novel drugs. Curr Opin Microbiol 1998; 1: 547-57.
16. Kontoyiannis DP, Mantadakis E, Samonis G. Systemic mycoses in the immunocompromised host: an update in antifungal therapy. J Hosp Infect 2003; 53: 243-58.
17. Lamb D, Kelly D, Kelly S. Molecular aspects of azole antifungal action and resistanceé Drug Resist Updat 1999; 2: 390-402.
18. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10: 121-30.
19. Sar B, Monchy D, Vann M et al. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J Antimicrob Chemother 2004; 54: 563-5.
20. Berg J, Clancy CJ, Nguyen MH. The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin Infect Dis 1998; 26: 186-7.
21. Armengou A, Porcar C, Mascaro J et al. Possible development of resistance to fluconazole during suppressive therapy for AIDSassociated cryptococcal meningitis. Clin Infect Dis 1996; 23: 1337-8.
22. Paugam A, Dupouy-Camet J, Blanche P et al. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin Infect Dis 1994; 19: 975-6.
23. Bicanic T, Harrison T, Niepieklo A et al. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006; 43: 1069-73.
24. Friese G, Discher T, Fussle R et al. Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease. AIDS 2001; 15: 2344-5.
25. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2009; 47: 117-23.
26. Nicholls MW. Polymyxin sensitivity of Candida tropicalis. J Med Microbiol 1970; 3: 529-38.
27. Schwartz SN, Medoff G, Kobayashi GS et al. Antifungal properties of polymyxin B and its potentiation of tetracycline as an antifungal agent. Antimicrob Agents Chemother 1972; 2: 36-40.
28. Falla TJ, Karunaratne DN, Hancock RE. Mode of action of the antimicrobial peptide indolicidin. J Biol Chem 1996; 271: 19298-303.
29. Xiang X, Zuo W, Efimov VP et al. Isolation of a new set of Aspergillus nidulans mutants defective in nuclear migration. Curr Genet 1999; 35: 626-30.
30. Tsai HF, Wheeler MH, Chang YC et al. A developmentally regulated gene cluster involved in conidial pigment biosynthesis in Aspergillus fumigatus. J Bacteriol 1999; 181: 6469-77.
31. Chong CR, Chen X, Shi L et al. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol 2006; 2: 415-6.
32. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts-Second Edition: Approved Standard M27-A2. NCCLS,Wayne, PA, USA, 2002.
33. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
34. Moneib NA. In-vitro activity of commonly used antifungal agents in the presence of rifampin, polymyxin B and norfloxacin against Candida albicans. J Chemother 1995; 7: 525-9.
35. Kwa A, Kasiakou SK, Tam VH et al. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther 2007; 5: 811-21.
36. Srimal S, Surolia N, Balasubramanian S et al. Titration calorimetric studies to elucidate the specificity of the interactions of polymyxin B with lipopolysaccharides and lipid A. Biochem J 1996; 315: 679-86.
37. Vaara M. Agents that increase the permeability of the outer membrane. Microbiol Rev 1992; 56: 395-411.
38. Hancock RE, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother 1999; 43: 1317-23.
39. Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related peptide antibiotics. Annu Rev Biochem 1977; 46: 723-63.
40. Teuber M, Bader J. Action of polymyxin B on bacterial membranes. Binding capacities for polymyxin B of inner and outer membranes isolated from Salmonella typhimurium G30. Arch Microbiol 1976; 109: 51-8.
41. Hancock RE. Peptide antibiotics. Lancet 1997; 349: 418-22.
42. HsuChen CC, Feingold DS. The mechanism of polymyxin B action and selectivity toward biologic membranes. Biochemistry 1973; 12: 2105-11.
43. Teuber M, Miller IR. Selective binding of polymyxin B to negatively charged lipid monolayers. Biochim Biophys Acta 1977; 467: 280-9.
44. Jandrositz A, Turnowsky F, Hogenauer G. The gene encoding squalene epoxidase from Saccharomyces cerevisiae: cloning and characterization. Gene 1991; 107: 155-60.
45. Anderson JB. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat Rev Microbiol 2005; 3: 547-56.
46. Cowen LE. The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nat Rev Microbiol 2008; 6: 187-98.
47. Lupetti A, Danesi R, Campa M et al. Molecular basis of resistance to azole antifungals. Trends Mol Med 2002; 8: 76-81.
48. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001; 39: 183-90.
49. Casadevall A, Perfect JR. Cryptococcus neoformans. Washington, DC: ASM Press, 1998.
50. Dannaoui E, Abdul M, Arpin M et al. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother 2006; 50: 2464-70.
51. Litvintseva AP, Mitchell TG. Most environmental isolates of Cryptococcus neoformans var. grubii (serotype A) are not lethal for mice. Infect Immun 2009; 77: 3188-95.
52. Litvintseva AP, Marra RE, Nielsen K et al. Evidence of sexual recombination among Cryptococcus neoformans serotype A isolates in sub-Saharan Africa. Eukaryot Cell 2003; 2: 1162-8.
53. Litvintseva AP, Thakur R, Vilgalys R et al. Multilocus sequence typing reveals three genetic subpopulations of Cryptococcus neoformans var. grubii (serotype A), including a unique population in Botswana. Genetics 2006; 172: 2223-38.
54. Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ et al. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 2002; 21: 212-4.
55. Jimenez-Mejias ME, Becerril B, Marquez-Rivas FJ et al. Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with intravenous colistin sulfomethate sodium. Eur J Clin Microbiol Infect Dis 2000; 19: 970-1.
56. Segal-Maurer S, Mariano N, Qavi A et al. Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. Clin Infect Dis 1999; 28: 1134-8.
57. Benifla M, Zucker G, Cohen A et al. Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E. J Antimicrob Chemother 2004; 54: 290-2.
58. Michalopoulos A, Falagas ME. Colistin and polymyxin B in critical care. Crit Care Clin 2008; 24: 377-91, x.
59. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999; 33: 960-7.
60. Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-11.
61. Garrod LP, O'Grady F, Barber M. Antibiotic and Chemotherapy. Baltimore: Williams and Wilkins, 1971.
62. Stein A, Raoult D. Colistin: an antimicrobial for the 21st century? Clin Infect Dis 2002; 35: 901-2.
63. Savage PB, Li C, Taotafa U et al. Antibacterial properties of cationic steroid antibiotics. FEMS Microbiol Lett 2002; 217: 1-7.
64. Vaara M, Vaara T. Sensitization of Gram-negative bacteria to antibiotics and complement by a nontoxic oligopeptide. Nature 1983; 303: 526-8.
65. Sanders WE Jr, Sanders CC. Toxicity of antibacterial agents: mechanism of action on mammalian cells. Annu Rev Pharmacol Toxicol 1979; 19: 53-83.
66. Stansly PG, Schlosser ME. Studies on polymyxin: isolation and identification of Bacillus polymyxa and differentiation of polymyxin from certain known antibiotics. J Bacteriol 1947; 54: 549-56.
67. Li J, Nation RL, Milne RW et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005; 25: 11-25.
68. Matsuzaki K, Nakamura A, Murase O et al. Modulation of magainin 2-lipid bilayer interactions by peptide charge. Biochemistry 1997; 36: 2104-11.
69. Matsuzaki K, Sugishita K, Harada M et al. Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria. Biochim Biophys Acta 1997; 1327: 119-30.
70. Bearer EL, Friend DS. Anionic lipid domains: correlation with functional topography in a mammalian cell membrane. Proc Natl Acad Sci USA 1980; 77: 6601-5.
71. Ogita A, Nagao Y, Fujita K et al. Amplification of vacuole-targeting fungicidal activity of antibacterial antibiotic polymyxin B by allicin, an allyl sulfur compound from garlic. J Antibiot (Tokyo) 2007; 60: 511-8.
72. Mason AJ, Marquette A, Bechinger B. Zwitterionic phospholipids and sterols modulate antimicrobial peptide-induced membrane destabilization. Biophys J 2007; 93: 4289-99.
73. Ahmad I, Perkins WR, Lupan DM et al. Liposomal entrapment of the neutrophil-derived peptide indolicidin endows it with in vivo antifungal activity. Biochim Biophys Acta 1995; 1237: 109-14.
74. Falla TJ, Hancock RE. Improved activity of a synthetic indolicidin analog. Antimicrob Agents Chemother 1997; 41: 771-5.
75. Garibotto FM, Garro AD, Masman MF et al. New small-size peptides possessing antifungal activity. Bioorg Med Chem 2010; 18: 158-67.
76. Perfect JR, Lang SD, Durack DT. Chronic cryptococcal meningitis: a new experimental model in rabbits. Am J Pathol 1980; 101: 177-94.
77. Winzeler EA, Shoemaker DD, Astromoff A et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 1999; 285: 901-6.
78. Nierman WC, Pain A, Anderson MJ et al. Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature 2005; 438: 1151-6.
79. Ma LJ, Ibrahim AS, Skory C et al. Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet 2009; 5: e1000549.